IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | Material Management Information related to Judgment of Investment(IND Approval Determination)(항암면역치료백신 BVACE6E7의 제1/2a상 임상시험 계획승인) | 2024-11-19 | |
| 9 | Material Management Information related to Judgment of Investment(Study Results)(COVID19 예방 백신 AdCLDCoV191 OMI의 제1/2상 임상시험 결과) | 2024-11-06 | |
| 8 | Release from designation as Investment Alert Issue & Prior notice on Re-designation | 2024-09-20 | |
| 7 | Designation as Investment Alert Issue | 2024-09-03 | |
| 6 | Release from designation as Investment Risk Issue | 2024-09-03 | |
| 5 | Additional Listing(유상증자(구주주배정)) | KOSDAQ STOCK MKT. | 2024-08-20 |
| 4 | Trade suspension and resumption (under the designation as Investment Risk Issue) | 2024-08-19 | |
| 3 | Prior notice on trade suspension | 2024-08-16 | |
| 2 | Response to Request for Inquired Disclosure (Significant Change in Stock Trading Activities) : Denial | 2024-08-13 | |
| 1 | Request for Inquired Disclosure(Significant Change in Stock Trading Activities) | KOSDAQ STOCK MKT. | 2024-08-12 |
